Monocyte apoptosis in patients with active lupus
The prcscncc of nucleosome polymers in the peripheral blood of patients with active systemic lupus erythematows (SLE) (1) suggests ongoing apoptosis. While the lymphocyte population has been implicated as a source of these fragments (2) , thc cells that release the chromatin are incompletely characterized. Our group has reported that patients with active lupus have a T cell subsct which spontaneously lyses autologous macrophagcs in vitro (3) , and that murine T cells capable of inducing apoptosis in syngcneic macrophages will cause a lupus-like disease in vivo (4) . These results suggest that monocyteimacrophage apoptosis may occur in patients with active lupus. Wc therefore sought to determine whcthcr patients with active lupus have evidence of ongoing monocyte apop tosis.
Patients with active lupus were recruited from the inpatient rheumatology servicc and outpatient clinics at the A University of Michigan, and paticnts with inactive lupus and active rheumatoid arthritis (RA) wcrc recruited from the outpatient clinics. Hcalthy control subjccts were obtained by advertising. Paticnts met the American College of liheumatology (formerly, the Amcrican Rhcumatism Association) criteria for the classification of SLE ( 5 ) or RA (6) . SLE and KA activity were defined as previously described (3) . Patients receiving cyclophosphamide were excluded from study. Some samples were stored as heparinized whole blood overnight at 23°C. In these cases, care was taken to store both patient and control samples under identical conditions. All samples wcrc analyzed within 20 hours of phlebotomy.
To detect apoptotic cells, peripheral blood mononuclear cells (PBMC) were isolated as described (3) , and stained with propidium iodidc (PI) and Hoescht 33342, and then analyzed by flow cytomctry (7, 8) . The lymphocyte, monocytc, and granulocyte populations were identified by forward and 90" light scatter and confirmed by staining with anti-CD3-FITC, anti-B1 -FITC, and anti-MO1-FITC (Coulter, Ilialeah, FL). Dead cells were identified by high PI staining, viable cells by low PI staining and 2N IIoescht DNA staining, and apoptotic cells by low PI staining and less than 2N Hoescht DNA staining (7, 8) . Where indicated, T cells were depletcd by rosetting with sheep erythrocytes (3), and the nonrosetting population was fixed and analyzed by transmission clcctron microscopy (TEM) as described (4) . Differences between groups were tested by analysis of variance, using SYSTAT software (Evanston, IL), or by t-tests.
PBMC were obtained from 10 paticnts with activc SLE, 8 patients with inactive SLE, 7 patients with activc RA, and 12 healthy controls. The cells were stained as describcd above, and the percentages of apoptotic monocytes and lymphocytes were determined by flow cytometry. Figure 1A shows a representative histogram of monocytcs from a hcalthy control. Figurc 1B shows monocytcs from a patient with active lupus analyzed similarly. In Figure lB , the population of cclls excluding PI, and containing less DNA than controls by Hoescht staining, contains thc apoptotic cells (7, 8) . Figure 2A shows that an average of 5% of the mono-
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LogDNALogDNA - Figure 1 . Peripheral blood mononuclear cells from A, a hcalthy control and R, a patient with activc lupus were stained with anti-MO1-FII'C, propidium iodidc, and Hocscht 33342 and analyzed using 3-color flow cytomctry. 'I'hc monocytc population is shown. The x axis (Log DNA) rcprcscnts the intcnsity of thc Hocscht staining; thc y axis (Log Viability) represents the PI staining intensity. The unlabelled z (vertical) axis rcprcscnts the cell nurnbcr. cytes from patients with active lupus were undergoing apoptosis, while <1% of monocytes from the other subjects wcrc apoptotic (P = 0.007). Figure 2B shows that a lesser number of lymphocytes from the same subjects were apoptotic, with an average of 2% for thc patients with active S I E and 50.6% for the other groups. However, this difference was not statistically significant (P = 0.06), possibly due to the number of subjects analyzed. Since some of the lupus patients had received corticosteroids, the effcct of methylprednisolonc on monocyte apoptosis was examincd. Mood samples wcrc obtained before and after administration of 1 gm of methylprednisolone. No significant increases were observed immediately (mean r+_ SEM 0.85 t 0.35% before and 1.75 _f 1.34% after, n = 2) or up to 3 days later (1.2% versus 0.5%). Furthcrmore, 5 of the SLE patients receiving a mean t SEM of 54 t 7.6 mgiday of prednisone had only 0.34 r+_ 0.16% apoptotic monocytes. Overall, the levcl of monocytc apoptosis was 4.2 t 1.9% in patients receiving 515 mg of prednisone/day, and 1.9 f 1.0% in patients receiving >I5 mgiday (P > 0.20). This finding supports thc notion that corticosteroids do not stimulate monocyte apoptosis.
The prescnce of apoptotic monocytes was confirmed by morphology in 2 subjects with active SLE. Figure 2C shows a representative micrograph of freshly obtained and isolated non-T cells stained with toluidine bluc from one of thcsc subjects, and 2D shows a 1 E M image. Monocytic cells show nuclear condensation, which is characteristic of apoptotic cells. Such cells were not seen in similar preparations from a normal subject (data not shown). To further examine the relationship between disease activity and monocyte apoptosis, two subjects with active SLE and increased numbers of circulating apoptotic monocytes were retested following therapy and with remission of symptoms. In both subjccts, the percentage of apoptotic monocytes dccreascd (from 8.1% to 096, and from 10% to 3.1%).
A recent report described accelerated lymphocyte apoptosis in patients with active SLE (2) . Howcvcr, other cell types were excluded from analysis in this study. Our results suggest that monocytes are also dying by apoptosis in patients with active lupus. Since some of the samples were analyzed 16-20 hours after phlebotomy, it is possible that some degree of apoptosis began between the time of phlebotomy and the time of staining. However, in SLE patient samples analyzed within hours of phlebotomy, apoptotic monocytes were also seen. Furthermore, the ultrastructural studies were also performed on freshly isolated cells, and also showed apoptotic cells. This argues that at least some degree of monocyte apoptosis occurs in vivo.
Earlier work suggested that cells other than just lymphocytes undergo apoptosis in SLE patients. The hematoxylin body, characteristic of lupus (9,10), histologically and chemically resembles apoptotic nuclei (ll), and is believed to derive from leukocytes, lymphocytes, macrophages, and endothelial cells (10) . Apoptotic monocytes and lymphocytes may contribute to the development of this structure. The signal-triggering apoptosis in these cells is unknown. The Fas molecule transmits an apoptosis-inducing signal in lymphocytes and monocytes (12, 13) , and is functional in SLE patients (13), which suggests a possible mechanism. Since a T cell subset capable of lysing syngeneic macrophages has been described in patients with active lupus (3), and T cells can express a Fas ligand (14), an autoreactive T cell subset could be responsible. Alternatively, monocyte and lymphocyte apoptosis could be the result of as yet unidentified stimuli generated during active disease. In either case, apoptotic cells could contribute to the pathogenesis of the disease. Recent evidence suggests that anti-DNA antibodies preferentially react with nucleosomes (15) . Nucleosomal DNA fragments, released from apoptotic blood elements, could provide an antigen source contributing to the development of anti-DNA autoantibodies. 
